Filtered By:
Management: Centers for Disease Control and Prevention (CDC)
Vaccination: Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 416 results found since Jan 2013.
Mini Review on Clinical Aspects of Monkeypox
Curr Pharm Biotechnol. 2023 Sep 14. doi: 10.2174/1389201025666230914094444. Online ahead of print.ABSTRACTMonkeypox is a disease caused by the monkeypox virus, which is a type of orthopox virus that comes from the virus family Poxviridae. Its first case reported in animals and humans was in 1958 and 1970, respectively. It is a viral zoonosis disease with two modes of transmission: animal to human (via direct contact or eating the meat of an infected animal) and human to human (via contact or contact with skin lesions, body fluids, and infected person's contaminated objects). The literature depicts that monkeypox is less co...
Source: Current Pharmaceutical Biotechnology - September 15, 2023 Category: Biotechnology Authors: Yash Saraswat Kamal Shah Source Type: research
Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial
We examined virus shedding after two doses of mOPV1 with and without fIPV, and after the first mOPV1 or bOPV dose. The trial is registered at ClinicalTrials.gov (NCT03722004).FINDINGS: During 18 December 2018 - 23 November 2019, 1,192 infants were enrolled (arms A:301; B:295; C:298; D:298). Immune responses at 14 weeks did not differ after two mOPV1 doses alone (94% [95% CI: 91-97%]) versus two mOPV1 doses with fIPV at 6 weeks (96% [93-98%]) or 10 weeks (96% [93-98%]). Participants who received mOPV1 and fIPV at 10 weeks had significantly lower shedding (p < 0ยท001) one- and two-weeks later compared with mOPV1 alone. Re...
Source: Vaccine - August 31, 2023 Category: Allergy & Immunology Authors: Cynthia J Snider Khalequ Zaman Amanda L Wilkinson Asma Binte Aziz Mohammad Yunus Warda Haque Kathryn A V Jones Ling Wei Concepcion F Estivariz Jennifer L Konopka-Anstadt Bernardo A Mainou Jaymin C Patel Jacquelyn S Lickness Mark A Pallansch Steven G F Was Source Type: research
Pneumococcal Vaccination in Adults
Am J Nurs. 2023 Sep 1;123(9):48-51. doi: 10.1097/01.NAJ.0000978148.47780.7f.ABSTRACTThe Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recently updated the adult pneumococcal vaccine recommendations to include two new pneumococcal conjugate vaccines (PCVs): PCV15 and PCV20. The authors review the updated guideline recommendations, their advantages and disadvantages, and nursing implications.PMID:37615467 | DOI:10.1097/01.NAJ.0000978148.47780.7f
Source: The American Journal of Nursing - August 24, 2023 Category: Nursing Authors: Joseph Walter Nicole Rudawsky Source Type: research
